secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001493152-25-021538
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q3 revenue $33.3M (+19% YoY); net income $1.3M vs loss
--------------------------------------------------------------------

- Revenue $33.3M (19% YoY); gross margin 66.1% vs 58.4%; net income $1.3M ($0.01 EPS) vs loss $5.0M (-$0.04 EPS).
- Adjusted EBITDA $4.5M vs loss $1.0M in prior year quarter; cash from operations $4.6M (vs $1.7M used).
- FY25 revenue guidance reiterated $131-135M (+11-15% YoY).
- Pending sale of non-core Coflex/CoFix assets and OUS businesses to Companion Spine expected to close by year-end 2025.
- Launched CollagenX bovine collagen particulate for surgical wound closure; potential across entire biologics portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315225021538/0001493152-25-021538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315225021538/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer